Literature DB >> 34626752

The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products.

Jinpeng Li1, Ricardo Carvajal2, Leon Bruner3, Norbert E Kaminski4.   

Abstract

The popularity of cannabidiol (CBD) in consumer products is soaring as consumers are using CBD for general health and well-being as well as to seek relief from ailments especially pain, inflammation, anxiety, depression, and sleep disorders. However, there are limited data currently in the public domain that provide support for these benefits. By contrast, a significant amount of safety evaluation data for CBD have been obtained recently from pre-clinical and clinical studies of the CBD therapeutic Epidiolex®. Yet some key data gaps concerning the safe use of CBD still remain. Furthermore, current regulations on CBD use in consumer products remain uncertain and often conflict between the state and federal level. In light of the rapidly expanding popularity of CBD-related products in the marketplace, here we review the current understanding of the benefits, safety, and regulations surrounding CBD in consumer products. This review does not advocate for or against the use of CBD in consumer products. Rather this review seeks to assess the state-of-the-science on the health effects and safety of CBD, to identify critical knowledge gaps for future studies, and to raise the awareness of the current regulations that govern CBD use in consumer products.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CBD regulations; Cannabidiol; Cannabinoid; Consumer products; Hemp; Ingredient safety

Mesh:

Substances:

Year:  2021        PMID: 34626752      PMCID: PMC9028607          DOI: 10.1016/j.fct.2021.112600

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   5.572


  109 in total

Review 1.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

2.  Cannabidiol in treatment of refractory epileptic spasms: An open-label study.

Authors:  Aline Herlopian; Evan J Hess; James Barnett; Alexandra L Geffrey; Sarah F Pollack; Lauren Skirvin; Patricia Bruno; Jo Sourbron; Elizabeth A Thiele
Journal:  Epilepsy Behav       Date:  2020-03-10       Impact factor: 2.937

Review 3.  Cannabis, Cannabinoids, and Sleep: a Review of the Literature.

Authors:  Kimberly A Babson; James Sottile; Danielle Morabito
Journal:  Curr Psychiatry Rep       Date:  2017-04       Impact factor: 5.285

4.  Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors.

Authors:  Alline Cristina Campos; Frederico Rogério Ferreira; Francisco Silveira Guimarães
Journal:  J Psychiatr Res       Date:  2012-09-11       Impact factor: 4.791

Review 5.  The effects of cannabidiol on male reproductive system: A literature review.

Authors:  Renata K Carvalho; Monica L Andersen; Renata Mazaro-Costa
Journal:  J Appl Toxicol       Date:  2019-07-17       Impact factor: 3.446

6.  Influence of cannabinoids on somatic cells in vivo.

Authors:  A M Zimmerman; A Y Raj
Journal:  Pharmacology       Date:  1980       Impact factor: 2.547

7.  Potential role of the cannabinoid receptor CB1 in rapid eye movement sleep rebound.

Authors:  L Navarro; M Martínez-vargas; E Murillo-rodríguez; A Landa; M Méndez-díaz; O Prospéro-garcía
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 8.  Synergistic interactions between cannabinoid and opioid analgesics.

Authors:  Diana L Cichewicz
Journal:  Life Sci       Date:  2004-01-30       Impact factor: 5.037

9.  Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.

Authors:  Orrin Devinsky; Chloe Verducci; Elizabeth A Thiele; Linda C Laux; Anup D Patel; Francis Filloux; Jerzy P Szaflarski; Angus Wilfong; Gary D Clark; Yong D Park; Laurie E Seltzer; E Martina Bebin; Robert Flamini; Robert T Wechsler; Daniel Friedman
Journal:  Epilepsy Behav       Date:  2018-07-11       Impact factor: 2.937

10.  Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.

Authors:  Jerzy P Szaflarski; Elizabeth Martina Bebin; Gary Cutter; Jennifer DeWolfe; Leon S Dure; Tyler E Gaston; Pongkiat Kankirawatana; Yuliang Liu; Rani Singh; David G Standaert; Ashley E Thomas; Lawrence W Ver Hoef
Journal:  Epilepsy Behav       Date:  2018-08-09       Impact factor: 2.937

View more
  1 in total

1.  Cannabidiol and Cannabidiol Metabolites: Pharmacokinetics, Interaction with Food, and Influence on Liver Function.

Authors:  Kieran Shay Struebin Abbotts; Taylor Russell Ewell; Hannah Michelle Butterklee; Matthew Charles Bomar; Natalie Akagi; Gregory P Dooley; Christopher Bell
Journal:  Nutrients       Date:  2022-05-21       Impact factor: 6.706

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.